Sentences with phrase «directors of the oncology»

Patricia Spencer - Cisek of Queensbury, executive director of oncology services at Glens Falls Hospital's C.R. Wood Cancer Center, said her service on the jury made her feel that there is an urgency for reform.

12/17/2007 Dr. Barbara Parker Named Medical Director, UCSD Oncology Services Barbara Parker, M.D., professor of clinical medicine at the University of California, San Diego (UCSD), has been named Medical Director of Oncology Services at Moores UCSD Cancer Center and UCSD Medical Center.

He served as president to the Colorado Association of Naturopathic Physicians and is on the board of directors of the Oncology Association of Naturopathic Physicians.

Jess Higgins Kelley MNT is the director of the Oncology Nutrition Therapy Board Certification Program at the Nutrition Therapy Institute in Denver, Colorado.

Dr. Frank J DeFeis, Central Veterinary Associates» Senior Vice President and Director of Oncology, Acupuncture and Homeopathic Medicine, has achieved...

Not exact matches

«The shortage over many oncology drugs at that time was due to large manufacturers having quality problems and having to shut down,» said Valerie Jensen, associated director of the drug shortage staff at the FDA.

Dr. Clifford A. Hudis, Chief Executive Officer, American Society of Clinical Oncology Greg Simon, Executive Director, Cancer Moonshot Task Force, The White House Dr. Ken Robert Smith, Distinguished Professor of Family Studies and Population Science; Director, Utah Population Database, University of Utah Moderator: Clifton Leaf, Fortune

Participants included CEOs Jonathan Bush of Athenahealth, Ron Gutman of HealthTap, Dr. Clifford Hudis of the American Society of Clinical Oncology, Dr. Vivian Lee of University of Utah Health Care, VitalConnect CEO Nersi Nazari, James Park of Fitbit, and Andrew Witty of GSK, as well as President of Flex Health Solutions John Carlson, Multiple Myeloma Research Foundation Founder Kathy Giusti, Dr. Sanjay Gupta, Arianna Huffington, Andreessen Horowitz General Partner Vijay Pande, Parker Foundation President Sean Parker, Women's Alzheimer's Movement Founder Maria Shriver, and White House Cancer Moonshot Task Force Executive Director Greg Simon.

Matt Hanley is currently the Western Immuno - Oncology Regional Business Director for Bristol Myers Squibb, a leading worldwide oncology company based out of Princeton, NJ, bringing novel, therapeutic Immuno - Oncology products to cancer pOncology Regional Business Director for Bristol Myers Squibb, a leading worldwide oncology company based out of Princeton, NJ, bringing novel, therapeutic Immuno - Oncology products to cancer poncology company based out of Princeton, NJ, bringing novel, therapeutic Immuno - Oncology products to cancer pOncology products to cancer patients.

Professor Josep Tabernero, a member of the scientific committee for the EORTC - NCI - AACR Symposium and head of the medical oncology department at Vall d'Hebron University Hospital and director of the Vall d'Hebron Institute of Oncology, Barcelona, Spain, commented: «These are encouraging results, which show that galeterone has significant clinical activity in men with castration - resistant prostate cancer that fails to respond to otheoncology department at Vall d'Hebron University Hospital and director of the Vall d'Hebron Institute of Oncology, Barcelona, Spain, commented: «These are encouraging results, which show that galeterone has significant clinical activity in men with castration - resistant prostate cancer that fails to respond to otheOncology, Barcelona, Spain, commented: «These are encouraging results, which show that galeterone has significant clinical activity in men with castration - resistant prostate cancer that fails to respond to other drugs.

«We're trying to build models that describe how tumors grow and respond to therapy,» said Yankeelov, director of the Center for Computational Oncology at The University of Texas at Austin (UT Austin) and director of Cancer Imaging Research in the LIVESTRONG Cancer Institutes of the Dell Medical School.

«It's difficult to make contrived samples behave like actual cell - free nucleic acids, so that's been quite a challenge,» says Kelli Bramlett, director of R&D in clinical sequencing and oncology at Thermo Fisher Scientific in Waltham, Massachusetts.

Subha Madhavan, an oncology professor and director of the Innovation Center for Biomedical Informatics (ICBI) at Georgetown University Medical Center in Washington, D.C., was next to praise her experience with a PSM graduate, named Shruti Rao, who earned her degree in molecular biotechnology at George Washington University, also in the nation's capital.

We have estimated that up to 15 percent of patients will be candidates for dose optimization,» explained senior study author Javier F.Torres - Roca, MD, director of Clinical Research and associate member of the Department of Radiation Oncology at Moffitt.

«Although FDA approval is critically important for introducing a new screening test or algorithm, providers ultimately rely on guidance or guidelines to help them make the best decisions for their patients and want to understand advantages, disadvantages and unknowns associated with a new screening approach,» said Huh, who is a senior scientist for the UAB Comprehensive Cancer Center, Director of the UAB Division of Gynecologic Oncology, and is also a board member for both the American Society for Colposcopy and Cervical Pathology and the Society of Gynecologic Oncology.

«These results suggest that biology is not as deterministic as many scientists think,» says Andrew Feinberg, M.D., M.P.H., the King Fahd Professor of Medicine, Oncology, and Molecular Biology and Genetics at the Johns Hopkins University School of Medicine and director of the Center for Epigenetics in the Institute for Basic Biomedical Sciences.

«That's because we desperately need a new strategy to treat this lymphoma — many patients are resistant to currently available treatments,» says the study's senior investigator, Dr. Ari Melnick, Gebroe Family Professor of Hematology / Oncology and director of the Raymond and Beverly Sackler Center for Biomedical and Physical Sciences at Weill Cornell.

Professor Paolo Boffetta (MD), the Annals of Oncology associate editor for epidemiology and Director of the Institute of Translational Epidemiology at the Icahn School of Medicine at Mount Sinai in New York (USA), commented: «These results are extremely important in showing that reducing cancer mortality can be achieved: priority should be given to research in cancers with unfavourable trends, such as pancreatic cancer, and in reducing cancer mortality disparities, both between countries (Central / Eastern versus Western Europe), and within countries, for example, between socioeconomic groups.

«The results of the phase III clinical trial show that a target fusion biopsy detects more clinically significant prostate cancer,» said Art Rastinehad, DO, principal investigator of the study and director of interventonal urologic oncology at North Shore - LIJ's Arthur Smith Institute for Urology, in New Hyde Park, NY.

The study was led by Dr. Alexandre Zlotta, Director of Uro - Oncology at Mount Sinai Hospital, and researcher with the Lunenfeld - Tanenbaum Research Institute, part of Sinai Health System in Toronto, Canada, and Dr. Paul Boutros, Principal Investigator, Informatics and Bio-computing, Ontario Institute for Cancer Research (OICR).

Young people with body mass indexes (BMIs) over 30 are more likely to experience aggressive malignancies, says author Nathan A. Berger, MD, Hanna - Payne Professor of Experimental Medicine; director of the Center for Science, Health and Society; member of the Case Comprehensive Cancer Center; and professor of medicine, biochemistry, oncology and genetics at Case Western Reserve University School of Medicine.

Until now, EGFR inhibitors have only been effective at treating the 10 to 15 percent of non-small cell lung cancers that have a variant of EGFR, but the two - drug combo could potentially work for all non-small cell lung cancers, explained Dr. John Minna, Director of the Hamon Center for Therapeutic Oncology Research and Professor of Internal Medicine and Pharmacology.

Future studies are planned by Chang and other School of Medicine researchers — including senior author Kenneth R. Carson, MD, PhD, an assistant professor of oncology, and Graham Colditz, MD, DrPH, a cancer expert who also is associate director of prevention and control at Siteman Cancer Center at Washington University School of Medicine and Barnes - Jewish Hospital.

As director of the thyroid oncology program at the University of Kentucky at Lexington, Ain has one of the largest single - physician thyroid cancer practices in the country and more than 70 peer - reviewed publications to his name.

«While the presence of lymphocytes in tumors is often associated with better clinical outcomes, this research adds clarity on the diversity of T cells within the tumor environment and their influence on ovarian cancer outcomes,» says first author Kunle Odunsi, MD, PhD, FRCOG, FACOG, Deputy Director, M. Steven Piver Professor and Chair of Gynecologic Oncology, and Executive Director of the Center for Immunotherapy at Roswell Park.

Principal investigator Leena Gandhi, MD, PhD, director of the thoracic medical oncology program at Perlmutter Cancer Center at NYU Langone Health and associate professor of Medicine in the division of Medical Oncology at NYU School of Medicine, presented these findings April 16 at the American Association for Cancer Research (AACR) Annual Meeting 2018 in oncology program at Perlmutter Cancer Center at NYU Langone Health and associate professor of Medicine in the division of Medical Oncology at NYU School of Medicine, presented these findings April 16 at the American Association for Cancer Research (AACR) Annual Meeting 2018 in Oncology at NYU School of Medicine, presented these findings April 16 at the American Association for Cancer Research (AACR) Annual Meeting 2018 in Chicago.

These results are among the best in the field, offering a lot of hope to people with ALK - positive lung cancer,» says D. Ross Camidge, MD, PhD, director of thoracic oncology at the University of Colorado Cancer Center and the trial's principal investigator.

«We wondered whether we could make a safer and more tolerable form of DON by enhancing its brain penetration and limiting its exposure to the rest of the body and, thus, toxicity,» says Barbara Slusher, Ph.D., professor of neurology, medicine, psychiatry, neuroscience and oncology at the Johns Hopkins University School of Medicine and director of Johns Hopkins Drug Discovery.

«We found very high response rates to this treatment combination, which has the added benefit of having a much reduced risk of long - term organ damage compared to the highly toxic chemotherapy agents typically used for patients with relapsed Hodgkin lymphoma,» says Dr. Kelly, who is Program Director of the Pediatric Hematology / Oncology Service Line at the Women & Children's Hospital of Buffalo and holds an additional faculty appointment with the University at Buffalo.

«Although the effects of the drug were modest, we now know that we can influence the course of the disease, and we expect to build on this success with other drugs, including some already in development,» said senior author, Gary K. Schwartz, MD, professor of medicine and chief of hematology / oncology at NewYork - Presbyterian / Columbia University Medical Center and associate director of its Herbert Irving Comprehensive Cancer Center.

A neuro - oncology research team at Dartmouth's Norris Cotton Cancer Center, led by the Director Mark A. Israel, MD with first author Gilbert J. Rahme, PhD, recently identified the transcription factor Id4 as a suppressor of tumor cell invasion in glioblastoma.

This image shows F. Stephen Hodi, M.D., director of the Melanoma Treatment Center and director of the Center for Immuno - Oncology at Dana - Farber.

Second, we believe the vaccine may be particularly beneficial for a group of patients with the HLA - A2 type, which suggests that as we move forward, there may be advantages in targeting this population,» said John Yu, MD, vice chair of the Department of Neurosurgery, director of surgical neuro - oncology, medical director of the Brain Tumor Center and neurosurgical director of the Gamma Knife Program at Cedars - Sinai.

Working with collaborators, Dr. Yang and Dr. Michele Carbone, MD, PhD, director of the UH Cancer Center's Thoracic Oncology Program, found that at least some of the so far unknown anti-tumor activity of aspirin is through preventing HMBG1 activity.

«Every state now has mandatory newborn screening for the disease,» said Dr. Buchanan, Director of the Barrett Family Center for Pediatric Oncology at UT Southwestern.

Jean - Pierre Issa, MD, Director of the Fels Institute for Cancer Research and Molecular Biology at Temple University School of Medicine and co-Leader of the Cancer Epigenetics Program at the Fox Chase Cancer Center is lead author of the study, which has been published August 19 in the journal, Lancet Oncology.

In addition, the subgroup of patients with unmethylated MGMT promoter and HLA - A2 appear to particularly benefit,» said Patrick Y. Wen, MD, director of the Center for Neuro - Oncology at Dana - Farber Cancer Institute and professor of Neurology, Harvard Medical School, who will present the data at the conference.

«This study demonstrates the value of testing lung cancer tissue for an ALK rearrangement, and it underscores the potential of cancer genomics to target cancer treatments to each patient,» says the study's senior author, Pasi A. Jänne, MD, PhD, who is the director of the Lowe Center for Thoracic Oncology of Dana - Farber.

Commenting on the trial, Dr Alice Shaw, director of thoracic oncology at the Massachusetts General Hospital Cancer Centre in Boston, US, said: «This is the first randomised study to examine how a second generation ALK inhibitor compares to standard second line chemotherapy in ALK positive patients who failed the standard first line therapy, which currently is crizotinib.»

In 1996, I relinquished an endowed chair of oncology at UNC Chapel Hill to become the scientific director of the Division of Clinical Sciences at the National Cancer Institute (NCI) near Washington, D.C..

One could take Davis, who is the director of the Center for Environmental Oncology at the University of Pittsburgh Cancer Institute, to task on the same grounds used by critics against Rachel Carson, whose book, Silent Spring, launched the modern environmental movement: Davis unabashedly makes the case against toxins and their health toll without presenting the other point of view.

As of 1991, Dr. Jain is the Andrew Werk Cook Professor of Tumor Biology (Radiation Oncology) at Harvard Medical School, and director of the Edwin L. Steele Laboratory of Tumor Biology at Massachusetts General Hospital.

which complement existing CNIO research themes, says Maria Blasco, director of the Molecular Oncology Programme and winner of the 2002 ELSO career development award.?

Dr. Engelman is the principal investigator of his own laboratory at the Massachusetts General Hospital (MGH) Cancer Center, the director of thoracic oncology at MGH and the director of molecular therapeutics at the MGH Cancer Center.

The project builds on Dr. Slamon's previous work partially funded by CIRM to develop a drug that targets tumor initiating cells with UCLA's Dr. Zev Wainberg, assistant professor of hematology / oncology and Dr. Tak Mak, director, Campbell Family Institute of the University Health Network in Toronto, Canada.

Teeth and nails are good for measuring radiation because they pick up free radicals (atoms, or ions, with unpaired electrons) created by ionizing radiation and can retain them for long periods of time, says Harold Swartz, a Dartmouth Medical School professor of radiation oncology and director of the Dartmouth Biodosimetry Center for Medical Countermeasures against Radiation.

The third finding came through collaboration between Markowitz and Stanton L. Gerson, MD, director of the Case Comprehensive Cancer Center, UH Seidman Cancer Center, and the National Center for Regenerative Medicine, as well as the Asa and Patricia Shiverick - Jane Shiverick (Tripp) Professor of Hematological Oncology.

«Identification of these variations has helped the family to better understand why their children developed cancer and to plan for the future,» said co-author Kim Nichols, M.D., a member of the St. Jude Oncology department and director of the St. Jude Cancer Predisposition Division.

«Now that we know exactly how changes in EMSY spur cancer cell growth, we can start to design therapies to specifically target that activity and hopefully stop it,» says senior author Douglas Levine, MD, director of the Division of Gynecologic Oncology at NYU Langone and its Perlmutter Cancer Center.

«NYGC is thrilled to have this work be our first published example of the explosive power of collaborations between deeply invested biologists like those in the Simon lab including Elana Simon, and thoughtful bioinformatics scientists like Nicolas Robine and NYGC team, who worked together so effectively with the tools of genomic sequencing and analysis to discover this new chimeric protein and cancer target,» says Robert Darnell, head of Rockefeller's Laboratory of Molecular Neuro - Oncology, HHMI investigator, and president and scientific director of NYGC.